REJUVE THERAPEUTICS, INC.
Dead / Abandoned — Abandoned — no statement of use filed (as of 15 Dec 2025)
What this means for you
This application is over — abandoned 15 Dec 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98263876
- Mark type
- Stylized text
- Filed
- 09 Nov 2023
- Published for opposition
- 17 Sept 2024
- Abandoned
- 15 Dec 2025
- Attorney of record
- Karen Won
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for respiratory diseases and disorders; Pharmaceutical and biological preparations for use in pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing COPD, chronic bronchitis, mucus hypersecretion, emphysema, asthma, sleep apnea, pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and other diseases, disorders, and conditions affecting the lungs and airways; Pharmaceutical and biological preparations for preventing, diagnosing, treating and managing cancer, fibrotic diseases, NASH, Crohn's Disease, osteoarthritis, viral infections, and hepatitis C; Pharmaceutical and biological preparations for improving air flow obstruction, reduce neutrophils and secreted elastase, improve mucociliary clearance, increase lung cell viability, increase alveolar regeneration, reduce smooth muscle proliferation, regulate cartilage destruction, reduce inflammation; Therapeutic agents in the nature of nebulized peptides, monoclonal antibodies, and recombinant protein domains for reversing underlying mechanisms of COPD
- Class 042 — Scientific and technological services: Research and development in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases; Providing medical scientific research information in the fields of pharmaceuticals, biologics, and therapeutic treatments in the fields of pulmonology, immunology, oncology, infectious diseases, and degenerative diseases
Owner
- Rejuve Therapeutics, Inc., Houston, TX, US
- Rejuve Therapeutics, Inc., Houston, TX, US
Prosecution history
- 15 Dec 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 15 Dec 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 02 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 May 2025 — SOU EXTENSION 1 GRANTED
- 01 May 2025 — SOU EXTENSION 1 FILED
- 01 May 2025 — SOU TEAS EXTENSION RECEIVED
- 12 Nov 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Sept 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Sept 2024 — PUBLISHED FOR OPPOSITION
- 28 Aug 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 14 Aug 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Aug 2024 — EXAMINER'S AMENDMENT ENTERED
- 13 Aug 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 13 Aug 2024 — EXAMINERS AMENDMENT E-MAILED
- 13 Aug 2024 — EXAMINERS AMENDMENT -WRITTEN